New mRNA bird flu vaccine enters human testing
NCT ID NCT07019883
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 25 times
Summary
This early-stage study tests a new mRNA vaccine designed to protect against bird flu (H5N1). About 80 healthy adults aged 18-49 will receive two doses of the vaccine. Researchers will closely monitor safety and measure the body's immune response over about 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AVIAN INFLUENZA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Baylor College of Medicine
Houston, Texas, 77030-3411, United States
-
Duke Vaccine and Trials Unit
Durham, North Carolina, 27703, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-0011, United States
Conditions
Explore the condition pages connected to this study.